GTx, Inc. (NASDAQ: GTXI) announced today there will be two scientific
poster presentations on the effects of enobosarm, a selective androgen
receptor modulator (SARM), on improving physical function and quality of
life in middle aged and elderly cancer patients. The posters will be
displayed on October 26th and 27th, 2012, at the
12th Meeting of the International Society of Geriatric Oncology to be
held at the Manchester Central Convention Centre in Manchester, United
Kingdom. Ryan P. Taylor, PhD, GTx's Associate Director of Medical
Affairs, will present data from the company's Phase IIb clinical study
of enobosarm, providing evidence that enobosarm may play an important
role in the management of cancer patients with muscle wasting by
improving physical function and quality of life, regardless of baseline
weight loss or age.
The first poster presentation will present data exploring patient
response to treatment by grouping subjects according to their baseline
weight loss (less or greater than 5% in the 6 month period prior to
randomization), and the age of the patient (above and below the median
age of 66 years). Of the 159 subjects randomized into the study, 103 had
physical function (by stair climb test) assessed at both baseline and
following 16 weeks of treatment and 24% of these subjects had lost less
than 5% of weight. Significant improvement in physical function was
observed in enobosarm treated subjects, while placebo subjects failed to
improve, regardless of baseline weight loss or age.